`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`GRÜNENTHAL GMBH,
`Petitioner
`
`v.
`
`ANTECIP BIOVENTURES II LLC,
`Patent Owner
`
`
`
`Case PGR2017-00022
`U.S. Patent No. 9,408,862 B2
`
`
`
`DECLARATION OF BRENT A. JOHNSON IN SUPPORT OF PATENT
`OWNER’S REPLY TO PETITIONER’S OPPOSITION TO PATENT
`OWNER’S CORRECTED CONTINGENT MOTION TO AMEND
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`
`
`ANTECIP EXHIBIT 2034
`Grunenthal GMBH v. Antecip Bioventures II LLC
`PGR2017-00022
`
`
`
`U.S. Patent No. 9,408,862
`
`
`
`PGR2017-00022
`
`I, BRENT A. JOHNSON, hereby declare and state as follows:
`
`1.
`
`I am a member of the law firm of Maschoff Brennan and counsel for
`
`the patent owner in the above-captioned matter, Antecip Bioventures II LLC.
`
`(“Patent Owner”). I am over the age of twenty-one years and make this declaration
`
`based on my own first-hand knowledge and observations. If called upon to testify
`
`to any of the facts or perceptions set forth herein, I could and would competently
`
`do so.
`
`2.
`
`Filed herewith as Exhibit 2035 is a true and correct copy of a screen
`
`shot of the Skelid drug label taken from the U.S. Food and Drug Administration’s
`
`website, https://www.fda.gov (“FDA website”). I personally visited the URL
`
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020707s006lbl.pdf on
`
`May 9, 2018, and reviewed its contents. I hereby confirm that the screen shot
`
`correctly and accurately depicts the images and text presented to me on that day.
`
`3.
`
`Filed herewith as Exhibit 2036 is a true and correct copy of the Skelid
`
`drug label taken from the FDA website. I personally visited the URL
`
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020707s006lbl.pdf on
`
`May 9, 2018, downloaded the Skelid drug label, and reviewed its contents. I
`
`hereby confirm that the Skelid drug label correctly and accurately depicts the
`
`images and text presented to me on that day.
`
`1
`
`
`
`U.S. Patent No. 9,408,862
`
`
`
`PGR2017-00022
`
`4.
`
`Filed herewith as Exhibit 2037 is a true and correct copy of a
`
`screenshot of the Didronel drug label taken from the FDA website. I personally
`
`visited the URL
`
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf on
`
`May 29, 2018, and reviewed its contents. I hereby confirm that the screen shot
`
`correctly and accurately depicts the images and text presented to me on that day.
`
`5.
`
`Filed herewith as Exhibit 2038 is a true and correct copy of the
`
`Didronel drug label taken from the FDA website. I personally visited the URL
`
`https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017831s055lbl.pdf on
`
`May 29, 2018, downloaded the Didronel drug label, and reviewed its contents. I
`
`hereby confirm that the Didronel drug label correctly and accurately depicts the
`
`images and text presented to me on that day.
`
`6.
`
`The Board may take judicial notice of facts that are “not subject to
`
`reasonable dispute” that “can be accurately and readily determined from sources
`
`whose accuracy cannot reasonably be questioned.” Fed. R. Evid. 201. Patent
`
`Owner hereby requests the Board take judicial notice of Exs. 2036 and 2038, drug
`
`labels publicly available on the FDA’s website. See Daniels–Hall v. Nat'l Educ.
`
`Ass'n, 629 F.3d 992, 998–99 (9th Cir.2010) (finding it appropriate to take judicial
`
`notice of information made publicly available on government websites where the
`
`authenticity of the information was not challenged).
`
`2
`
`
`
`U.S. Patent No. 9,408,862
`
`
`
`PGR2017-00022
`
`7.
`
`Filed herewith as Exhibit 2039 is a true and correct copy of a
`
`screenshot of the purchase of the article Serum kinetics, bioavailability and bone
`
`scanning of 99mTc-labelled sodium olpadronte in patients with different rates of
`
`bone turnover taken from the Springer International Publishing website,
`
`https://www.springer.com/us (“Springer website”). I personally visited the URL
`
`https://checkout.springer.com/checkout/cart?1&wt_mc=ThirdParty.SpringerLink.3
`
`.EPR653.AbstractPage_Article-new on May 9, 2018, and reviewed its contents. I
`
`hereby confirm that the screen shot correctly and accurately depicts the images and
`
`text presented to me on that day.
`
`8.
`
`Filed herewith as Exhibit 2040 is a true and correct copy of the receipt
`
`of the purchase of the article Serum kinetics, bioavailability and bone scanning of
`
`99mTc-labelled sodium olpadronte in patients with different rates of bone turnover
`
`from the Springer Website. I personally visited the URL
`
`https://checkout.springer.com/checkout/cart?1&wt_mc=ThirdParty.SpringerLink.3
`
`.EPR653.AbstractPage_Article-new on May 9, 2018, purchased the article, and
`
`reviewed the receipt I received upon purchase. I hereby confirm that the receipt
`
`correctly and accurately depicts the images and text represented to me on that day.
`
`9.
`
`Filed herewith as Exhibit 2041 is a true and correct copy of the article
`
`Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium
`
`olpadronte in patients with different rates of bone turnover from the Springer
`
`3
`
`
`
`U.S. Patent No. 9,408,862
`
`
`
`PGR2017-00022
`
`Website. I personally visited the URL
`
`https://checkout.springer.com/checkout/cart?1&wt_mc=ThirdParty.SpringerLink.3
`
`.EPR653.AbstractPage_Article-new on May 9, 2018, purchased the article, and
`
`downloaded it upon purchase. I hereby confirm that the article correctly and
`
`accurately depicts the images and text represented to me on that day.
`
`
`
`
`
`I declare under penalty of perjury that the foregoing is true and correct.
`
`
`
`
`
`By:
`
`
`Executed on June 1, 2018,
`
` /Brent A. Johnson/
` Brent A. Johnson
`
`4
`
`